Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Ipilimumab [USAN:INN]
RN: 477202-00-9
UNII: 6T8C155666

Notes

  • An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
  • An anti-cytotoxic T lymphocyte-associated antigen 4 antibody for treatment of metastatic melanoma and other cancers.

    NCI: A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. (NCI Thesaurus)

Molecular Formula

  • C6472-H9972-N1732-O2004-S40
 

Classification Codes

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Treatment of Oncology Disease and HIV Infection

Names and Synonyms

Name of Substance

  • Ipilimumab
  • Ipilimumab [USAN:INN]

MeSH Heading

  • Ipilimumab

Synonyms

  • Anti-CTLA4
  • Immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human gamma1-chain), disulfide with human kappa-chain, dimer
  • Ipilimumab
  • MDX 010
  • MDX-010
  • MDX-CTLA 4
  • MDX-CTLA-4
  • Monoclonal antibody MDX-010
  • UNII-6T8C155666
  • Yervoy

Registry Numbers

CAS Registry Number

  • 477202-00-9

FDA UNII

  • 6T8C155666

Other Registry Number

  • 799813-32-4

System Generated Number

  • 0477202009